Sri Yarlagadda is a Nephrology physician. OpenAlex indexes 34 publications with 2,740 citations (h-index 13).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
3901 Rainbow Blvd
Ms 3002
Kansas City, KS 66160
Telephone
913-588-6074Provider last certified this registry record 3 Apr 2026.
Industry payments
2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Baxter HealthcareProgram year20231 payment
- Fresenius USA Marketing, Inc.Program year20211 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
60.7%Loop diuretic15.5%Furosemide65%Bumetanide18%Torsemide18%Part D<11 patientsAngiotensin receptor blocker (ARB)10.7%Losartan Potassium100%Part D≥18 patients+ 6 more classes in this area
Metabolism & gastrointestinal
31.6%SGLT2 inhibitor23.6%Jardiance74%Farxiga26%Part D<11 patientsPotassium supplement5%Potassium Chloride100%Part D<11 patients+ 1 more class in this area
Other
4.8%Phosphate Binder4.8%Sevelamer Carbonate100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Rituximab or cyclosporine A for the treatment of membranous nephropathy: economic evaluation of the MENTOR trial
Nephrology Dialysis Transplantation
2024 - TRENDS OF PULMONARY EMBOLISM AND CLINICAL OUTCOMES IN END STAGE KIDNEY DISEASE PATIENTS FROM 2011 TO 2019 IN THE UNITED STATES
Journal of the American College of Cardiology
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Giuseppe Remuzzi
Mario Negri Institute for Pharmacological Research
Marcello Tonelli
University of Calgary
Johan Ärnlöv
Dalarna University
Juan Jesús Carrero
Danderyds sjukhus
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”